PL3043785T3 - Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych - Google Patents

Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych

Info

Publication number: PL3043785T3
Authority: PL; Poland
Prior art keywords: ketamine; pharmaceuticals; salt; application
Prior art date: 2013-09-13

Application number

PL14793319T

Other languages

English (en)

Inventor

Kenji Hashimoto

Original Assignee

National University Corporation Chiba University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-09-13

Filing date

2014-09-12

Publication date

2022-02-28

2014-09-12 Application filed by National University Corporation Chiba University filed Critical National University Corporation Chiba University

2022-02-28 Publication of PL3043785T3 publication Critical patent/PL3043785T3/pl

Links

239000003814 drug Substances 0.000 title 1
229960003299 ketamine Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PL14793319T 2013-09-13 2014-09-12 Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych PL3043785T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2013190066		2013-09-13
EP14793319.6A EP3043785B1 (en)	2013-09-13	2014-09-12	Application of r-ketamine and salt thereof as pharmaceuticals
PCT/JP2014/004730 WO2015037248A1 (en)	2013-09-13	2014-09-12	Application of r-ketamine and salt thereof as pharmaceuticals

Publications (1)

Publication Number	Publication Date
PL3043785T3 true PL3043785T3 (pl)	2022-02-28

Family

ID=51846870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14793319T PL3043785T3 (pl)	2013-09-13	2014-09-12	Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych

Country Status (16)

Country	Link
US (5)	US9872841B2 (pl)
EP (2)	EP3043785B1 (pl)
JP (7)	JP6366439B2 (pl)
CA (2)	CA3143962A1 (pl)
CY (1)	CY1125290T1 (pl)
DK (1)	DK3043785T3 (pl)
ES (1)	ES2897453T3 (pl)
HR (1)	HRP20211629T1 (pl)
HU (1)	HUE056378T2 (pl)
LT (1)	LT3043785T (pl)
PL (1)	PL3043785T3 (pl)
PT (1)	PT3043785T (pl)
RS (1)	RS62516B1 (pl)
SI (1)	SI3043785T1 (pl)
SM (1)	SMT202100641T1 (pl)
WO (1)	WO2015037248A1 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111643449A (zh)	2013-03-15	2020-09-11	詹森药业有限公司	S-盐酸氯胺酮的药物组合物
SI3043785T1 (sl) *	2013-09-13	2022-02-28	National University Corporation Chiba University	Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
KR20170054470A (ko)	2014-09-15	2017-05-17	얀센 파마슈티카 엔.브이.	VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
US20160332962A1 (en)	2015-05-13	2016-11-17	Janssen Pharmaceutica Nv	(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CA2987909C (en)	2015-06-27	2022-04-26	Shenox Pharmaceuticals, Llc	Ketamine transdermal delivery system
US11110070B2 (en)	2015-11-17	2021-09-07	The Trustees Of Columbia University In The City Of New York	Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
JPWO2018079693A1 (ja)	2016-10-27	2019-10-31	国立大学法人千葉大学	（ｓ）−ノルケタミンおよびその塩の医薬品としての応用
JP2021003001A (ja) *	2017-09-07	2021-01-14	国立大学法人千葉大学	うつ症状の検査方法、及び治療薬のスクリーニング方法
US20200009081A1 (en)	2017-09-13	2020-01-09	Janssen Pharmaceutica N.V.	Delivery Of Esketamine For The Treatment Of Depression
WO2019065900A1 (ja) *	2017-09-27	2019-04-04	国立大学法人千葉大学	神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
WO2019094596A1 (en)	2017-11-09	2019-05-16	The Trustees Of Columbia University In The City Of New York	Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
US11491120B2 (en)	2017-11-09	2022-11-08	The Trustees Of Columbia University In The City Of New York	Pharmacological prophylactics against stress-induced affective disorders in females
KR20200113197A (ko)	2017-12-22	2020-10-06	얀센 파마슈티칼즈, 인코포레이티드	우울증 치료를 위한 에스케타민
EP3753557A4 (en) *	2018-02-15	2021-12-01	National University Corporation Chiba University	PROPHYLACTIC OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION AGAINST INFLAMMATORY DISEASES OR BONE DISEASES
MX2020011653A (es) *	2018-05-04	2021-02-09	Perception Neuroscience Inc	Métodos de tratamiento para el abuso de sustancias.
US11154537B2 (en)	2018-08-10	2021-10-26	Eleusis Therapeutics Us, Inc.	Method of treatment for ketamine infusion
EP3903775A4 (en) *	2018-12-27	2022-10-12	National University Corporation Chiba University	R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
IL318198A (en)	2019-03-05	2025-03-01	Janssen Pharmaceuticals Inc	Esketamine for the treatment of depression
AU2020324432A1 (en) *	2019-08-05	2021-10-07	The Ketamine Research Foundation	Ketamine for the treatment of postpartum symptoms and disorders
CN112125816A (zh) *	2020-03-17	2020-12-25	国药集团工业有限公司	一种氯胺酮、其衍生物或其盐的消旋化方法
US12144786B2 (en)	2020-03-27	2024-11-19	Homeostasis Therapeutics LLC	Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes
CN114306219B (zh) *	2020-09-30	2023-09-26	四川普锐特药业有限公司	稳定的r-氯胺酮药物组合物
WO2022118783A1 (ja) *	2020-12-04	2022-06-09	国立大学法人大阪大学	治療抵抗性うつ病または緊急性を有するうつ病の症状を治療するための組成物
IL312041A (en)	2021-10-12	2024-06-01	Perception Neuroscience Inc	R-ketamine salts and methods of using them
JP2025509517A (ja)	2022-03-14	2025-04-11	パーセプションニューロサイエンス，インコーポレイティド	Ｒ－ケタミンの医薬製剤
CN115006375A (zh) *	2022-06-24	2022-09-06	华中科技大学	艾司氯胺酮用于制备治疗社交障碍药物的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3254124A (en)	1962-06-29	1966-05-31	Parke Davis & Co	Aminoketones and methods for their production
CH535201A (de)	1969-12-19	1973-03-31	Bristol Myers Co	Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
US4670459A (en)	1984-10-03	1987-06-02	Merrell Dow Pharmaceuticals Inc.	Method of alleviating withdrawal symptoms
US5543434A (en)	1994-02-25	1996-08-06	Weg; Stuart L.	Nasal administration of ketamine to manage pain
US5679714A (en)	1995-06-07	1997-10-21	Weg; Stuart L.	Administration of ketamine for detoxification and treatment of tobacco addiction
DE19619665C2 (de)	1996-05-15	2001-03-08	Goedecke Ag	Racemattrennung von Ketamin
US7001609B1 (en)	1998-10-02	2006-02-21	Regents Of The University Of Minnesota	Mucosal originated drug delivery systems and animal applications
US6382204B1 (en)	1999-10-14	2002-05-07	Becton Dickinson And Company	Drug delivery system including holder and drug container
US6962151B1 (en)	1999-11-05	2005-11-08	Pari GmbH Spezialisten für effektive Inhalation	Inhalation nebulizer
CA2400929C (en)	2000-02-23	2011-05-31	Amgen Inc.	Antagonistic selective binding agents of osteoprotegerin binding protein
BRPI0002693B8 (pt)	2000-06-19	2021-05-25	Cristalia Produtos Quim Farmaceuticos Ltda	processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
US7090830B2 (en)	2001-05-24	2006-08-15	Alexza Pharmaceuticals, Inc.	Drug condensation aerosols and kits
EP1551393A4 (en)	2002-07-30	2010-06-16	Peter Migaly	COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US7273889B2 (en)	2002-09-25	2007-09-25	Innovative Drug Delivery Systems, Inc.	NMDA receptor antagonist formulation with reduced neurotoxicity
DE60327883D1 (de)	2002-11-18	2009-07-16	Yaupon Therapeutics Inc	Analgetische verwendung von (s)-norketamin
US7713440B2 (en)	2003-10-08	2010-05-11	Lyotropic Therapeutics, Inc.	Stabilized uncoated particles of reversed liquid crystalline phase materials
PT1928405E (pt)	2005-09-28	2014-10-20	Auris Medical Ag	Composições farmacêuticas para o tratamento de distúrbios do ouvido interno
KR20090029690A (ko)	2006-03-22	2009-03-23	마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티	우울증을 치료하기 위한 케타민의 투여 방법
US20120225949A1 (en) *	2009-08-14	2012-09-06	Demitri Papalos	Compositions and methods for treating bipolar disorder
US20110038807A1 (en) *	2009-08-14	2011-02-17	Demitri Papolos	Compositions and methods for treating bipolar disorder
US20130236573A1 (en)	2012-03-12	2013-09-12	Janssen Pharmaceutica Nv	Esketamine for the treatment of treatment-refractory or treatment-resistant depression
US20140057988A1 (en)	2012-08-23	2014-02-27	Stuart WEG	Anxiolytic composition, formulation and method of use
CN111643449A (zh)	2013-03-15	2020-09-11	詹森药业有限公司	S-盐酸氯胺酮的药物组合物
SG11201507358VA (en)	2013-03-15	2015-10-29	Janssen Pharmaceutica Nv	Pharmaceutical composition of s-ketamine hydrochloride
CN105377371A (zh)	2013-04-12	2016-03-02	西奈山伊坎医学院	创伤后应激障碍的治疗方法
SI3043785T1 (sl)	2013-09-13	2022-02-28	National University Corporation Chiba University	Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
US9610259B2 (en)	2014-01-14	2017-04-04	Children's Hospital Medical Center	Compositions and methods for treating an autism spectrum disorder
MX2017001908A (es)	2014-08-13	2017-08-08	Janssen Pharmaceutica Nv	Metodo para el tratamiento de la depresion.
EP3085366A1 (en)	2015-04-22	2016-10-26	Institut du Cerveau et de la Moelle Epiniere-ICM	Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US11426366B2 (en)	2015-05-15	2022-08-30	Arizona Board Of Regents On Behalf Of The Universsity Of Arizona	Compositions and methods for treating motor disorders
US11110070B2 (en)	2015-11-17	2021-09-07	The Trustees Of Columbia University In The City Of New York	Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2019065900A1 (ja)	2017-09-27	2019-04-04	国立大学法人千葉大学	神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
EP3753557A4 (en)	2018-02-15	2021-12-01	National University Corporation Chiba University	PROPHYLACTIC OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION AGAINST INFLAMMATORY DISEASES OR BONE DISEASES
MX2020011653A (es)	2018-05-04	2021-02-09	Perception Neuroscience Inc	Métodos de tratamiento para el abuso de sustancias.
EP3903775A4 (en)	2018-12-27	2022-10-12	National University Corporation Chiba University	R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodevelopmental disorder
CA3140046A1 (en)	2019-05-15	2020-11-19	Bexson Biomedical, Inc.	Ketamine formulation for subcutaneous injection

2014
- 2014-09-12 SI SI201431903T patent/SI3043785T1/sl unknown
- 2014-09-12 EP EP14793319.6A patent/EP3043785B1/en active Active
- 2014-09-12 PT PT147933196T patent/PT3043785T/pt unknown
- 2014-09-12 HR HRP20211629TT patent/HRP20211629T1/hr unknown
- 2014-09-12 CA CA3143962A patent/CA3143962A1/en active Pending
- 2014-09-12 WO PCT/JP2014/004730 patent/WO2015037248A1/en active Application Filing
- 2014-09-12 PL PL14793319T patent/PL3043785T3/pl unknown
- 2014-09-12 SM SM20210641T patent/SMT202100641T1/it unknown
- 2014-09-12 HU HUE14793319A patent/HUE056378T2/hu unknown
- 2014-09-12 EP EP21192664.7A patent/EP3964203A1/en active Pending
- 2014-09-12 LT LTEPPCT/JP2014/004730T patent/LT3043785T/lt unknown
- 2014-09-12 ES ES14793319T patent/ES2897453T3/es active Active
- 2014-09-12 DK DK14793319.6T patent/DK3043785T3/da active
- 2014-09-12 JP JP2014186056A patent/JP6366439B2/ja active Active
- 2014-09-12 RS RS20211346A patent/RS62516B1/sr unknown
- 2014-09-12 US US15/021,003 patent/US9872841B2/en active Active
- 2014-09-12 CA CA2923685A patent/CA2923685C/en active Active
2017
- 2017-12-21 US US15/849,698 patent/US10406121B2/en active Active
2018
- 2018-07-03 JP JP2018126684A patent/JP6615277B2/ja active Active
2019
- 2019-07-26 US US16/522,815 patent/US11207279B2/en active Active
- 2019-11-01 JP JP2019199496A patent/JP6842206B2/ja active Active
2021
- 2021-02-11 JP JP2021020280A patent/JP2021073310A/ja active Pending
- 2021-11-16 US US17/527,693 patent/US20220071929A1/en not_active Abandoned
- 2021-11-24 CY CY20211101022T patent/CY1125290T1/el unknown
2022
- 2022-11-27 JP JP2022188797A patent/JP7398836B2/ja active Active
2023
- 2023-11-28 JP JP2023200421A patent/JP7627514B2/ja active Active
- 2023-12-19 US US18/545,395 patent/US20240382436A1/en active Pending
2025
- 2025-01-20 JP JP2025007274A patent/JP2025061458A/ja active Pending

Also Published As

Publication number	Publication date
CA2923685C (en)	2022-03-08
LT3043785T (lt)	2021-12-10
DK3043785T3 (da)	2021-11-15
JP6615277B2 (ja)	2019-12-04
US20220071929A1 (en)	2022-03-10
SMT202100641T1 (it)	2022-01-10
JP2018145207A (ja)	2018-09-20
JP6842206B2 (ja)	2021-03-17
EP3964203A1 (en)	2022-03-09
JP2021073310A (ja)	2021-05-13
JP2020015766A (ja)	2020-01-30
SI3043785T1 (sl)	2022-02-28
RS62516B1 (sr)	2021-11-30
ES2897453T3 (es)	2022-03-01
CY1125290T1 (el)	2023-03-24
US20160220513A1 (en)	2016-08-04
WO2015037248A1 (en)	2015-03-19
US10406121B2 (en)	2019-09-10
EP3043785A1 (en)	2016-07-20
PT3043785T (pt)	2021-11-05
CA3143962A1 (en)	2015-03-19
US11207279B2 (en)	2021-12-28
JP6366439B2 (ja)	2018-08-01
US20180177745A1 (en)	2018-06-28
JP7627514B2 (ja)	2025-02-06
JP2023011027A (ja)	2023-01-20
CA2923685A1 (en)	2015-03-19
HRP20211629T1 (hr)	2022-02-04
JP2024009274A (ja)	2024-01-19
US9872841B2 (en)	2018-01-23
JP2025061458A (ja)	2025-04-10
JP7398836B2 (ja)	2023-12-15
JP2015078181A (ja)	2015-04-23
EP3043785B1 (en)	2021-08-25
US20240382436A1 (en)	2024-11-21
US20190343781A1 (en)	2019-11-14
HUE056378T2 (hu)	2022-02-28

Publication	Publication Date	Title
HUE056378T2 (hu)	2022-02-28	R-Ketamin és sójának alkalmazása gyógyszerekként
IL274355B (en)	2021-02-28	Aza-pyridone compounds and their uses
IL243608A0 (en)	2016-02-29	Substances with antiviral activity, preparations containing them and their uses
GB201323008D0 (en)	2014-02-12	Compounds and uses thereof
SG11201507897SA (en)	2015-11-27	Salt of pyrazoloquinoline derivative, and crystal thereof
SG11201506713TA (en)	2015-09-29	2-acylaminothiazole derivative and salt thereof
EP3054974A4 (en)	2017-06-14	Glycan-interacting compounds and methods of use
PT2967044T (pt)	2018-02-27	Composição herbicida e seu método de uso
IL243614A0 (en)	2016-02-29	Consequences of mutated pyrazolylpyrazole and its use as a herbicide
IL243613B (en)	2019-01-31	Consequences of mutated pyrazolylpyrazole and its use as a herbicide
IL243615A0 (en)	2016-02-29	Consequences of mutated pyrazolylpyrazole and its use as a herbicide
TWI562776B (en)	2016-12-21	Pharmaceutical composition and uses thereof
GB201307233D0 (en)	2013-05-29	Compounds and uses thereof
GB201312698D0 (en)	2013-08-28	Preparation and use of zinc compounds
GB201309180D0 (en)	2013-07-03	Compounds and Their Uses
GB201307082D0 (en)	2013-05-29	Pharmaceutical composition comprising 15-HETrE and methods of using the same
IL240177A0 (en)	2015-09-24	Converted chromium-6-yloxy-cycloalkanes and their use as drugs
GB201314610D0 (en)	2013-10-02	Compounds and their uses
GB201306248D0 (en)	2013-05-22	Compounds and their uses
IL240447A (en)	2017-07-31	Propionic Acid-Baryl Acid Derivatives and Their Use as Pharmaceutical Preparations
IL243616A0 (en)	2016-02-29	Consequences of mutated pyrazolylpyrazole and its use as a herbicide
GB201518882D0 (en)	2015-12-09	Agrochemical composition and method of use thereof
IL240422A0 (en)	2015-09-24	Bi-aryl derivatives of propionic acid and their use as medicinal preparations
EP3052475A4 (en)	2017-05-03	Pharmaceutical use of 3-benzylsulfonylpropionitrile
AU2013902711A0 (en)	2013-08-08	Compounds and methods of their use - IV